Consensus guidelines for the management and treatment of neuroendocrine tumors

• Published in: Pancreas Vol. 42; no. 4; p. 557
• Main Authors: Kunz, Pamela L, Reidy-Lagunes, Diane, Anthony, Lowell B, Bertino, Erin M, Brendtro, Kari, Chan, Jennifer A, Chen, Herbert, Jensen, Robert T, Kim, Michelle Kang, Klimstra, David S, Kulke, Matthew H, Liu, Eric H, Metz, David C, Phan, Alexandria T, Sippel, Rebecca S, Strosberg, Jonathan R, Yao, James C
• Format: Journal Article
• Language: English
• Published: United States 01.05.2013
• Subjects: Biomarkers, Tumor - metabolism; Humans; Molecular Targeted Therapy; Neuroendocrine Tumors - metabolism; Neuroendocrine Tumors - pathology; Neuroendocrine Tumors - therapy; North America; Societies, Medical; North America
• ISSN: 1536-4828
• DOI: 10.1097/MPA.0b013e31828e34a4

Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.